Cas:26257-13-6 Calcium bis(hydroxyacetate) manufacturer & supplier

Chemical Name:Calcium bis(hydroxyacetate)

CAS.NO:26257-13-6

Synonyms:calcium 2-hydroxyacetate;CalciuM Glycolate;Calcium bis(hydroxyacetate);GLYCOLIC ACID CALCIUM SALT;Glycolic Acid Calcium SaltHydroxyacetic Acid Calcium Salt;Acetic acid, 2-hydroxy-, calcium salt (2:1);calcium 2-hydroxyethanoate;Hydroxyacetic Acid Calcium Salt

Molecular Formula:C₄H₆CaO₆

Molecular Weight:190.165

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:265.6ºC at 760mmHg

Density:N/A

Index of Refraction:

PSA:120.72000

Exact Mass:189.979034

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like calcium 2-hydroxyacetate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Hydroxyacetic Acid Calcium Salt physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,calcium 2-hydroxyacetate Use and application,GLYCOLIC ACID CALCIUM SALT technical grade,usp/ep/jp grade.

Related News: The memo denies the company made false statements to the FDA. In their complaint, employees said they were broadly concerned that quality control documents the FDA requires companies to maintain had been rewritten or fabricated. The employees did not specify whether these materials had been shown to the FDA. Calcium bis(hydroxyacetate) manufacturer Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world. Calcium bis(hydroxyacetate) supplier Slower growth in pesticide intermediates weighed on industrial business. In the first three quarters, the company’s operating income was 2.977 billion yuan, a year-on-year increase of 2.57%. Calcium bis(hydroxyacetate) vendor The memo denies the company made false statements to the FDA. In their complaint, employees said they were broadly concerned that quality control documents the FDA requires companies to maintain had been rewritten or fabricated. The employees did not specify whether these materials had been shown to the FDA. Calcium bis(hydroxyacetate) factory It’s a disturbing set of events, scientifically, clinically, politically, Karlawish said.